Previous Close | 3.4200 |
Open | 3.3800 |
Bid | 2.4050 x 0 |
Ask | 2.5100 x 0 |
Day's Range | 3.3800 - 3.3950 |
52 Week Range | 0.9420 - 4.4000 |
Volume | |
Avg. Volume | 12 |
Market Cap | 103.725M |
Beta (5Y Monthly) | 2.44 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Insight into Neuronetics' Financial Health and Strategic Advances
Neuronetics (STIM) delivered earnings and revenue surprises of 18.18% and 1.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.